What were the primary drivers of Amgen's revenue growth in the second quarter of 2003?

Amgen's revenue growth was primarily driven by a substantial increase in product sales, which rose by 72% year-over-year to $1,916.5 million. Key contributors to this growth included strong performance from ENBREL®, Aranesp®, and NeulastaTM, as well as the continued sales momentum of EPOGEN® and NEUPOGEN®.

How did the acquisition of Immunex impact Amgen's financial results for this quarter?

The acquisition of Immunex, completed in July 2002, had a significant positive impact on Amgen's second quarter 2003 results. The financial statements for the current period include the consolidated operations of Immunex, contributing to the overall increase in total revenues and product sales. This acquisition has expanded Amgen's product base and pipeline.

What is the company's liquidity position and outlook?

Amgen maintains a strong liquidity position, with cash, cash equivalents, and marketable securities totaling $4,985.4 million as of June 30, 2003. The company generated $1,720.5 million in cash from operating activities during the first six months of 2003. Amgen believes its existing funds, cash generated from operations, and debt financing sources are adequate to meet its working capital and capital expenditure requirements and to support its stock repurchase program.

Are there any significant legal or contingent matters that investors should be aware of?

Yes, Amgen is involved in ongoing legal proceedings. Notably, a legal award of $151.2 million (including interest) was received in Q4 2002 from Johnson & Johnson for breach of a license agreement, with an additional $74.0 million awarded for costs and expenses in May 2003. The company also faces other litigation, such as shareholder lawsuits and patent-related disputes, which it believes will not have a material adverse effect on its financial statements.

AMGN 10-Q Quarterly Report Q2 FY2003 — Revenue, Net Income, EPS

Summary

Amgen Inc. reported strong financial performance for the second quarter of 2003, driven by significant growth in product sales, largely attributable to ENBREL®, Aranesp®, and NeulastaTM. Total revenues for the quarter reached $2.04 billion, a substantial increase from the prior year, reflecting the successful integration and performance of recently acquired assets, particularly Immunex. The company demonstrated robust operating income and net income, underscoring its operational efficiency and market position. Key financial highlights include a 72% year-over-year increase in product sales, a testament to the growing demand for Amgen's key therapeutic areas. The company also maintained a healthy cash flow from operations, providing ample liquidity for ongoing investments and strategic initiatives. While the company faces ongoing litigation and regulatory considerations, its financial position appears solid, supported by strong product sales and a comprehensive product pipeline. Investors should note the significant impact of the Immunex acquisition on the current period's results and the continued investment in research and development.

Key Highlights

1Total revenues for the quarter ended June 30, 2003, increased to $2,041.1 million, a 72% increase from $1,249.1 million in the prior year period.
2Product sales saw a significant surge of 72% year-over-year, reaching $1,916.5 million, primarily driven by ENBREL®, Aranesp®, and NeulastaTM.
3Operating income grew to $817.1 million, up from $564.8 million in the same period last year, reflecting improved operational leverage.
4Net income increased to $607.2 million, or $0.45 per diluted share, compared to $412.4 million, or $0.38 per diluted share, in the prior year.
5The acquisition of Immunex, completed in July 2002, is significantly contributing to the current period's revenue and product sales growth, with its results now consolidated.
6Cash provided by operating activities was $1,720.5 million for the six months ended June 30, 2003, demonstrating strong cash generation capabilities.
7Amgen recorded a $74.0 million award in January 2003 related to a legal arbitration with Johnson & Johnson, contributing to 'Other items, net'.

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2003

Summary

Key Highlights

Frequently Asked Questions